Encouraging fibromyalgia study results now available at ClinicalTrials.gov

http://goo.gl/ouPcxw

The study was conducted by The University of California, San Diego and the Department of Veterans Affairs. The study results, also published in the Society for Neuroscience (SfN) annual meeting and poster program, indicated the 28 day AVACEN follow-up study exhibited a statistically significant reduction of over 40% in the widespread pain index and a decrease in tender point count to a level below the value typically used for the clinical assessment of fibromyalgia.

These results were derived from a treatment process that uses the palm to noninvasively transfer heat into the circulatory system while the body is at normothermia (approximately 98.6 degrees F). The Company refers to this process as the AVACEN Treatment Method.

Muehlbauer added, "Our patented AVACEN Treatment Method is an entirely new concept in chronic pain treatment through whole-body muscular relaxation. This is accomplished by bathing the skeletal muscles with warm oxygenated and nutritious blood. Our FDA-Cleared AVACEN 100 uses the AVACEN Treatment Method."

"The key is the continued infusion of heat into the circulatory system through the palm when the body is at normothermia, approximately 98.6 degrees F. The heat acts as a catalyst to reduce the thickness of the blood. The result is the body must dissipate the unwanted heat by pumping the warmed and thinner blood through the skeletal muscles to reach the heat exchange capillary network where it can be cooled by the ambient air. It should be noted that the level of heat is precisely controlled so that it cannot induce heatstroke. Actually, the level of infused heat normally doesn't even engage the sweat glands."